Pancreatic Cancer: Successful Trial Against Pancreatic Cancer with Defence Therapeutics' ARM-002 Anti-Cancer Vaccine #Chemicals #Pharmaceutical #Biotechnology #Medical #Pharmaceuticals #CSEStocks #OTC #OTCMarkets #OTCStocks #SmallCaps #Investing

Vancouver, British Columbia--(Newsfile Corp. - May 1, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology therapeutics and drug delivery technologies, is pleased to announce the successful completion of a pre-clinical vaccination trial using its ARM-002TM vaccine against pancreatic cancer. The vaccine was shown to be therapeutically effective against pre-established pancreatic...


http://dlvr.it/T6FtKT

Comments

Popular posts from this blog

ICEBERG Financial Announces New Fintech Product and Pre-Launch Institutional Contract #Banking #FinancialServices

Coelacanth Announces Q3 2023 Financial and Operating Results #CEI.CA #CEI.V #CEIEF #Earnings #Investing #OTC #OTCMarkets #OTCStocks #Oil #OilAndGas #QuarterlyResults #Results #SmallCaps #TSXV

Aurora Solar Technologies Corporate Update #AACTF #ACU.CA #ACU.V #AlternativeEnergy #AuroraSolarTech #CleanEnergy #CorporateUpdate #Energy #Investing #OTC #OTCMarkets #OTCStocks #RenewableEnergy #SmallCaps #Solar #TSXV